Clinical Trials
124 trialsA Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
National Cancer Institute (NCI)
LIGHT
Sun Yat-sen University
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Sun Yat-sen University
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
Sun Yat-sen University
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Sun Yat-sen University
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
Sun Yat-sen University
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
Sichuan Baili Pharmaceutical Co., Ltd.
Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
TRANSPARENT
Coherus Oncology, Inc.
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
First Affiliated Hospital of Guangxi Medical University
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Sun Yat-sen University
AcceleRET-Lung
Hoffmann-La Roche
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
Sun Yat-sen University
Magic-C002
Shanghai Miracogen Inc.
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
H. Lee Moffitt Cancer Center and Research Institute
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
National University Hospital, Singapore
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma
The University of Hong Kong
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
KEYVIBE-005
Merck Sharp & Dohme LLC
PLATINUM
Sun Yat-sen University
DIAMOND
Sun Yat-sen University
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
Eye & ENT Hospital of Fudan University
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Sun Yat-sen University
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Akeso
Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma
Fudan University
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Shanghai JMT-Bio Inc.
Metastatic Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
Akeso
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Sun Yat-sen University
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
City of Hope Medical Center
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
RATIONALE-309
BeiGene
GEMSTONE
Sun Yat-sen University
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
Sun Yat-sen University
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer
West China Hospital
PIPER
University of Malaya